Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 17575-22-3 Chemical Structure| 17575-22-3

Structure of Lanatoside C
CAS No.: 17575-22-3

Chemical Structure| 17575-22-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Lanatoside C is a cardiac glycoside, can be used in the treatment of congestive heart failure and cardiac arrhythmia.Lanatoside C has an IC50 of 0.19 μM for dengue virus infection in HuH-7 cells.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Lanatoside C

CAS No. :17575-22-3
Formula : C49H76O20
M.W : 985.12
SMILES Code : O[C@]([C@@](CC[C@@]1([H])[C@@]2(CC[C@H](O[C@@](O[C@H](C)[C@H]3O[C@@](O[C@H](C)[C@H]4O[C@@](O[C@H](C)[C@H]5O[C@]([C@@H]([C@@H](O)[C@@H]6O)O)([H])O[C@@H]6CO)([H])C[C@@H]5OC(C)=O)([H])C[C@@H]4O)([H])C[C@@H]3O)C1)C)([H])[C@]2([H])C[C@H]7O)(CC[C@@H]8C(CO9)=CC9=O)[C@]78C
MDL No. :MFCD00869432

Safety of Lanatoside C

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301
Precautionary Statements:P301+P310
Class:6.1
UN#:2811
Packing Group:

Isoform Comparison

Biological Activity

Description
Lanatoside C, a cardiac glycoside, is utilized in the management of congestive heart failure and cardiac arrhythmias. It demonstrates an IC50 of 0.19 μM against dengue virus in HuH-7 cells and is capable of inhibiting all four serotypes of dengue virus, as well as flavivirus Kunjin, alphavirus Chikungunya, Sindbis virus, and human enterovirus 71[1].[2].

In Vitro:

Cell Line
Concentration Treated Time Description References
Jurkat cells 2 μM 6 hours Lanatoside C significantly downregulated RUNX1 protein level EMBO Mol Med. 2025 Mar;17(3):563-588
Gli36 cells 0.25 μM 48 hours Lanatoside C enhances Gli36 cell sensitivity to TRAIL. Neuro Oncol. 2011 Nov;13(11):1213-24
HF19 primary human fibroblasts 0.25 μM 48 hours Lanatoside C shows no significant toxicity to normal fibroblasts. Neuro Oncol. 2011 Nov;13(11):1213-24
Primary GBM cells 0.25 μM 48 hours Lanatoside C significantly reduces the viability of primary GBM cells and enhances sensitivity to TRAIL. Neuro Oncol. 2011 Nov;13(11):1213-24
U87 cells 0.25 μM and 1 μM 16 hours Lanatoside C upregulates DR5 expression, enhancing GBM cell sensitivity to TRAIL-induced cell death. Neuro Oncol. 2011 Nov;13(11):1213-24
human brain endothelial cells 10 µM 24 hours Lanatoside C blocked IL-1β-induced inflammatory secretions including CCL2, sICAM-1, sVCAM-1, IL-6, IL-8, CX3CL1, RANTES, G-CSF, and GM-CSF Commun Biol. 2021 Feb 26;4(1):260
EL4 cells 2 μM 6 hours Lanatoside C significantly downregulated RUNX1 protein level EMBO Mol Med. 2025 Mar;17(3):563-588
MCF-7 1 μM or 5 μM 24 hours LanC suppressed the increase in GRP78 expression induced by Tg Neoplasia. 2021 Dec;23(12):1213-1226
SK-MEL-28 1 μM or 5 μM 24 hours LanC suppressed the increase in GRP78 expression induced by Tg Neoplasia. 2021 Dec;23(12):1213-1226
HeLa 1 μM or 5 μM 24 hours LanC suppressed the increase in GRP78 expression induced by Tg Neoplasia. 2021 Dec;23(12):1213-1226
SCC-25 1 μM or 5 μM 24 hours LanC suppressed the increase in GRP78 expression induced by Tg Neoplasia. 2021 Dec;23(12):1213-1226
A549 1 μM or 5 μM 24 hours LanC suppressed the increase in GRP78 expression induced by Tg Neoplasia. 2021 Dec;23(12):1213-1226
CFPAC-1 1 μM 24 hours LanC suppressed the increase in GRP78 expression induced by Tg, Tu, or 2-DG Neoplasia. 2021 Dec;23(12):1213-1226
PANC-1 1 μM 24 hours LanC suppressed the increase in GRP78 expression induced by Tg, Tu, or 2-DG, bringing its level close to that of untreated cells Neoplasia. 2021 Dec;23(12):1213-1226
GBM8 neural sphere cells 0.25 μM 24 hours To evaluate the effect of Lanatoside C combined with sTRAIL on the viability of GBM8 neural sphere cells. Results showed that GBM8 neural sphere cells were more sensitive to sTRAIL and Lanatoside C alone, and the combination treatment resulted in a significant decrease in cell viability (around 90%). Mol Oncol. 2016 Apr;10(4):625-34
U87 human glioblastoma cells 0.25 μM 24 hours To evaluate the effect of Lanatoside C combined with sTRAIL on the viability of U87 cells. Results showed that sTRAIL alone did not cause cell death, while 0.25 μM Lanatoside C alone caused approximately 50% cell death. The combination of sTRAIL and Lanatoside C resulted in a significant decrease in cell viability (around 80%). Mol Oncol. 2016 Apr;10(4):625-34
293T-NF+RC cells 10 μM 30 minutes Lanatoside C potently inhibited the interaction between FOXP3 and RUNX1 EMBO Mol Med. 2025 Mar;17(3):563-588
human brain pericytes 10 µM 24 hours Screening for compounds that modulate IL-1β-induced CCL2 and ICAM-1 expression, Lanatoside C showed anti-inflammatory effects Commun Biol. 2021 Feb 26;4(1):260

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice U87-Gluc-CFP subcutaneous xenograft model Intraperitoneal injection 6 mg/kg body weight Once daily for 10 days Lanatoside C alone or in combination with TRAIL significantly inhibits tumor growth, with combination therapy reducing tumor volume by more than 85%. Neuro Oncol. 2011 Nov;13(11):1213-24
BALB/c nude mice DLBCL xenograft model Intraperitoneal injection 6 mg/kg Every two days until the end of the experiment To evaluate the inhibitory effect of Lanatoside C on DLBCL tumor growth Leukemia. 2024 Feb;38(2):351-364
Athymic nude mice Intracranial U87 glioblastoma model Intraperitoneal injection 7.5 mg/kg Once daily for 5 days To evaluate the effect of Lanatoside C combined with AAV-sTRAIL on intracranial U87 tumors. Results showed that Lanatoside C treatment led to a significant decrease in tumor-associated Fluc signal, and tumors regrew rapidly after stopping treatment. Re-administration of Lanatoside C re-sensitized tumors to sTRAIL-induced cell death. The combination therapy significantly slowed tumor growth and prolonged mouse survival. Mol Oncol. 2016 Apr;10(4):625-34
C57BL/6J mice LLC allograft tumor model Intraperitoneal injection (IP) 6 mg/kg Every 2 days for 2 weeks Lanatoside C significantly inhibited the growth of LLC tumors EMBO Mol Med. 2025 Mar;17(3):563-588

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.02mL

0.20mL

0.10mL

5.08mL

1.02mL

0.51mL

10.15mL

2.03mL

1.02mL

References

 

Historical Records

Categories